Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV.
A recombinant retroviral system was used for the analysis of early HIV breakthrough infection in the presence of antiviral drugs. The use of replication-defective HIV allowed a quantitative analysis of a single cycle of infection. This report characterizes this recombinant HIV system and demonstrates it's validity in comparison to standard assays. It is demonstrated that the protease inhibitor XM323 inhibits both early and late events in the HIV life-cycle, while dextran sulphate inhibits only early events. In addition, it is shown that this system can be used for detecting and quantitating drug resistant HIV. Thus, the use of this system may provide both novel information about the stage of the viral life-cycle inhibited and a preliminary assessment of the mechanism(s) responsible for breakthrough infection in the presence of antiretroviral drugs.
Medina
D J
DJ
Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine, New Brunswick, Piscataway, USA.
Tung
P P
PP
Nelson
C J
CJ
Sathya
B
B
Casareale
D
D
Strair
R K
RK
D019380:Anti-HIV Agents / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D016264:Dextran Sulfate / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D005822:Genetic Vectors; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics* / Q000254:growth & development; D006367:HeLa Cells; D006801:Humans; D007763:Lac Operon; D008826:Microbial Sensitivity Tests; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D014162:Transfection; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D001381:Azepines; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; C085886:XM 323; D016264:Dextran Sulfate